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BACKGROUND: Patient misunderstanding of prescrip-
tion drug label instructions is a common cause of unin-
tentional misuse of medication and adverse health out-
comes. Thosewith limited literacy andEnglish proficiency
are at greater risk.
OBJECTIVE: To test the effectiveness of a patient-
centered drug label strategy, including a Universal Medi-
cation Schedule (UMS), to improve proper regimen use
and adherence compared to a current standard.
DESIGN: Two-arm, multi-site patient-randomized prag-
matic trial.
PARTICIPANTS:English- and Spanish-speaking patients
from eight community health centers in northern Virginia
who received prescriptions from a central-fill pharmacy
andwhowere 1)≥30 years of age, 2) diagnosedwith type 2
diabetes and/or hypertension, and 3) taking ≥2 oral
medications.
INTERVENTION: A patient-centered label (PCL) strategy
that incorporated evidence-based practices for format
and content, including prioritized information, larger font
size, and increased white space. Most notably, instruc-
tions were conveyed with the UMS, which uses standard
intervals for expressing when to take medicine (morning,
noon, evening, bedtime).
MAIN MEASURES: Demonstrated proper use of a multi-
drug regimen; medication adherence measured by self-
report and pill count at 3 and 9 months.
KEY RESULTS: A total of 845 patients participated in the
study (85.6 % cooperation rate). Patients receiving the
PCL demonstrated slightly better proper use of their drug
regimens at first exposure (76.9 % vs. 70.1 %, p = 0.06)
and at 9months (85.9% vs. 77.4%, p = 0.03). The effect of
the PCLwas significant for English-speaking patients (OR
2.21, 95 % CI 1.13–4.31) but not for Spanish speakers
(OR1.19, 95%CI 0.63–2.24). Overall, the intervention did
not improve medication adherence. However, significant
benefits from the PCL were found among patients with
limited literacy (OR 5.08, 95 % CI 1.15–22.37) and for
those with medications to be taken ≥2 times a day
(OR 2.77, 95 % CI 1.17–6.53).
CONCLUSIONS: A simple modification to pharmacy-
generated labeling, with minimal investment required,
can offer modest improvements to regimen use and ad-
herence, mostly among patients with limited literacy and
more complex regimens.
Trial Registration (ClinicalTrials.gov): NCT00973180,
NCT01200849
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health literacy; clinical trial; pharmacy.
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INTRODUCTION
Many studies have reported a high prevalence of patient misun-
derstanding of common prescription drug label instructions, and
its association with unintentional medication misuse and adverse
health outcomes.1–4 Those with limited literacy skills and En-
glish proficiency (LEP) are disproportionately at risk.2–9 The
manner in which physicians convey prescription instructions
and pharmacy labeling practices has consequently been scruti-
nized as possible root causes of the confusion.10–14 This body of
research has now been summarized at great length in numerous
seminal reports, all recognizing the urgent need to improve
written medication instructions and prescription labeling, both
to promote patient safety and to improve adherence.10,15–17
In 2008, the Institute of Medicine (IOM) issued a report
recognizing the need for setting standards within prescribing
and dispensing practices.10 In the report, the evidence for drug
labeling Bbest practices^ was summarized, and the concept of a
BUniversal Medication Schedule^ (UMS) was introduced. Spe-
cifically, given that an overwhelming majority of prescriptions
are reportedly taken four or fewer times a day, the UMS
establishes an equivalent number of standard time intervals
for the prescribing and dispensing of medicine (morning, noon,
evening, bedtime). This is designed to remove the previously
noted variability in the manner in which prescriptions are
written by physicians and transcribed by pharmacists. All
1482
Received April 12, 2016
Revised May 25, 2016
Accepted July 8, 2016
Published online August 19, 2016
prescriptions must instruct patients to take their medicine at one
or more of these specified times, and must be described in a
single standardized fashion. UMS instructions also include
simplified text, the use of numeric characters instead of words
to detail dose (B1^ instead of Bone^), and carriage returns
(placing each dose on a separate line) to clearly identify every
time a medicine is to be taken.18
Inmultiple efficacy trials, adults whowere shown drug labels
that included UMS instructions (e.g. Btake 1 tablet in the morn-
ing and 1 tablet at bedtime^) versus a current standard (e.g.
Btake 1 tablet twice daily^) were better able to demonstrate
proper dosing and spacing of medication.19–22 This has even
led to a reduction in known disparities, as adults with low
literacy benefited the most. These findings have since been
replicated in one international study23 and among LEP
patients.24 Despite extensive evidence supporting the UMS, a
major limitation is that testing to date has been conducted only
in hypothetical scenarios. In the present study, we tested the
effectiveness of an evidence-based, patient-centered drug label
strategy that included UMS instructions, in order to promote
proper medication use and adherence compared to a current
pharmacy best practice among actual patients following multi-
drug regimens. Our team capitalized on a unique opportunity to
partner with a central-fill pharmacy serving eight community
health centers in northern Virginia. Two sequential awards from
the Agency for Healthcare Research and Quality (AHRQ) were
merged into a single pragmatic trial; the first award was to study
the UMS among English-speaking patients, and the second
extended the evaluation to Spanish-speaking individuals.
METHODS
We conducted a two-arm, multi-site, patient-randomized prag-
matic trial of a patient-centered prescription drug labeling (PCL)
strategy to improve proper use and adherence. A description of
the trial is provided in greater detail in a previous publication.25
The primary goal of the study was to determine whether the PCL
strategy could improve 1) demonstrated proper use of prescribed
drug regimens and 2) subsequent adherence compared to the
current pharmacy standard. We hypothesized that this evidence-
based label would improve proper use, and that it might also
have a disproportionate benefit among those with limited literacy
and English proficiency, but also among patients with greater
regimen complexity. The outcome of medication adherence,
measured via self-report and pill count, was included as an
exploratory aim, as many barriers could exist that labeling would
not solve (e.g. side effects, cost). The study procedures were
approved by the institutional review boards (IRBs) at Northwest-
ern University and participating community health center sites,
as well as a national independent IRB service.
Participants
Study participants were patients seeking care between August
2009 and October 2012 from one of eight safety-net primary
care clinics located in northern Virginia and affiliated with
NoVA ScriptsCentral (NSC), a non-profit central-fill pharmacy.
NSC provides a subsidized prescription drug service to vulner-
able patients via courier delivery. Specifically, patients pay $5
per prescription for mostly 90-day fill orders for a limited
formulary of chronic medicines. Patients were eligible for en-
rollment if they 1) were 30 years of age or older, 2) had a
diagnosis of type 2 diabetes and/or hypertension, 3) were taking
two or more oral medications purchased through NSC, and 4)
were fluent in English or Spanish. Medical directors at each
clinic worked closely with NSC and gave approval for partic-
ipation in the study. Exclusion criteria included 1) an uncorrect-
able hearing or visual impairment, 2) inability to participate due
to illness, or 3) a cut-off score of 4 on the Six-Item Screener
(SIS) suggesting a significant cognitive impairment.26
Intervention
The PCL intervention comprised changes to prescription drug
container labeling, following only evidence-based practices
for information format and content, with labels placed on 40-
dram bottles containing a 90-day supply of a prescription.
Patients receiving the PCL had all prescriptions that were
being filled for them by NSC dispensed with this new label
structure. A detailed account of the evidence supporting label-
ing changes is described in the 2008 IOM report and also by
Shrank and colleagues.10,25 The acceptability of the labeling
was also supported by patient focus groups.21 Label changes
included dose instructions that were written in UMS form,
stating when to take a medication using one of four daily
standard time intervals (morning, noon, evening, bedtime). A
graphic aid was also placed in the center of the label, below the
instructions, to visually display the dose (number of pills) per
specified interval(s). In addition, the label prioritized patient
content via large, bolded font (12 point) and increased white
space; this included patient name, birth date, medication name
and dose, indication, and UMS instructions. The latter was
further highlighted by a light blue box pre-printed on the label
paper. Content that was deemed secondary but still useful to
patients as reference information was organized with attention
paid to sufficient white space, and placed to the right of the
primary content. The standard label arm followed a common
template used by a national pharmacy chain at the time of trial
initiation. Most importantly, the instructions followed a com-
mon standard not in UMS form. Figure 1 provides a sample of
both the PCL and standard label. Spanish translations of the
UMS instructions were undertaken previously following a
rigorous, patient-centered process that involved the use of
three bilingual, bicultural translators to independently translate
and then reconcile any discrepancies. A full description of the
translation process is available in an earlier publication.27
Randomization
A simple 1:1 randomization scheme was employed to assign
patients to either the PCL or standard care study arms. Eligible
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patients were identified via pharmacy and medical records,
and once consent was obtained, randomization was performed
using a random number generator. Two pharmacy labeling
printer systems were used; one generated the PCL label format
and the other the current label standard. Both labels were
programmed within the Cerner® Etreby Pharmacy Manage-
ment System software. A fixed field was included to identify
the printer each patient would be assigned to, and subsequent-
ly the label and instruction type they would receive for the
entire course of the study.
Outcomes
The primary outcomewas demonstrated proper use (yes or no)
of a prescribed drug in a patient’s regimen. This was measured
by the patient's ability to correctly report, for each medication,
all of the following: 1) howmany pills taken per dose, 2) times
per day a medicine was to be taken, specifying the hour of
each dose, and 3) the total number of pills taken daily. This has
served as a common outcome in prior studies.2,4,19–23 A reg-
imen summary score at the patient level was also calculated,
indicating whether the dosing of all medications a patient was
taking was correct. The secondary outcome under study was
adherence, measured via 1) self-report of missed or incorrect
doses in the prior 4 days using the Patient Medication Adher-
ence Questionnaire (PMAQ)28,29 and 2) pill count (for diabe-
tes and hypertensive medicines). Demonstrated proper use
was measured at baseline and at 3 and 9 months, whereas
adherence was assessed at 3 and 9 months.
In addition, literacy skills were measured at baseline
using the Rapid Estimate of Adult Literacy in Medicine
(REALM)30 among English-speaking patients, and the
Short Assessment of Health Literacy for Spanish Adults
(SAHLSA) among LEP Spanish-speaking patients.31 We
also collected general sociodemographic data (age, gender,
race/ethnicity, and education attainment), health status, and
general prescription regimen information (self-report of
number of medications taken).
Analysis
Response rates at 3- and 9-month follow-up were calculated
following the American Association of Public Opinion
Research (AAPOR) guidelines. Chi-square tests were first
used to compare patient-level outcomes by study arm. Gener-
alized linear models (GLM) were used for medication level
analyses separately at each time point. A generalized estimat-
ing equation (GEE) approach was used specifying a binomial
family and logit link for the dichotomous outcomes. Odds
ratios comparing the PCL strategy and standard label arms
were calculated using robust standard error estimates in con-
junction with standard repeated-measures GEE methodology.
Overall intervention effects were first examined for each out-
come, and models were repeated stratified by language to
determine whether estimates differed between English- and
Spanish-speaking participants. To determine whether the PCL
effects varied by patient and medication characteristics, inter-
action terms for group by each of the following were included
in additional models: literacy level (limited vs. adequate),
number of self-reported medications taken daily (<4, 4–5,
>5), and medication-specific variables including number of
times per day the medicine was taken (1 vs. 2 or more) and
medication class (antihypertensive/diuretic, diabetes [oral], or
statin). All statistical analyses were performed overall and
stratified by language using STATA version 12.1 software
(StataCorp LP, College Station, TX).
RESULTS
Participant Flow
A total of 851 patients in all were recruited, although only
845 had complete data and were included in the final sample
(see Fig. 2). The overall cooperation rate was 85.4 % among
Spanish-speaking patients and 85.9 % among English-
speaking patients. At 3 months, retention rates were
60.7 % among Spanish-speaking patients and 51.1 % among
English-speaking patients; by 9 months, the retention rates
were 65.2 % and 41.2 %, respectively. Spanish participants
were more likely than English-speaking participants to
complete the 9-month interview (Spanish 65 %, English
41 %, p < 0.001). Over half (56 %) of female participants
completed the 9-month interview, compared to 48 % of men
(p = 0.03). Attrition rates did not differ by arm, age, educa-
tion, or literacy level.
Fig. 1 Sample of patient-centered primary label using the Universal Medication Schedule (UMS).
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Baseline Data
The 845 patients included in these analyses were taking a total
of 2259 NSC-filled medications (1087 English, 1172 Span-
ish). The average regimen size at baseline, including all phar-
macies, was 3.8 medications among Spanish-speaking
patients and 4.6 medications among English-speaking
patients. Participants are described in Table 1, stratified by
both language spoken and study arm. There were differences
noted by language; Spanish-speaking patients were more like-
ly to be women (68.3% vs. 56.2%, p < 0.001) and to have less
than a high school education (61.5 % vs. 24.6 %, p < 0.001).
Outcomes
Demonstrated Proper Use.At baseline, with the first potential
exposure to the intervention, the overall rate of demonstrated
proper use of all medications in patients’ regimens was
71.8 %; the rate was slightly higher among those in the PCL
arm (76.9 %) compared to those in the standard arm (70.1 %,
p = 0.06). At 3 months, 80.3 % of the sample demonstrated
proper regimen use, with no differences between study arms
(82.6 % vs. 79.0 %, p = 0.35). By 9 months, the overall rate of
safe use was 80.8 %, and more patients demonstrated correct
use in the PCL arm than the standard care arm (85.9 % vs.
77.4 %, p = 0.03). This was confirmed in medication-level
GEE models; at 9 months, patients receiving the PCL were
more likely to demonstrate proper use than those receiving the
standard (odds ratio [OR] 1.67, 95 % confidence interval [CI]
1.06–2.63, p = 0.03, Table 2). When examining the effect of
the intervention by language, the PCL significantly improved
proper use for English-speaking patients (OR 2.21, 95 % CI
1.13–4.31, p = 0.02) but not for Spanish speakers (OR 1.19,
Fig. 2 CONSORT diagram.
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95 % CI 0.63–2.24, p = 0.59). Significant language-specific
interactions were found between receipt of the PCL interven-
tion and number of medications in a patient’s regimen. At
3 months, Spanish-speaking patients receiving the PCL who
were taking more complex drug regimens (>5 Rx medica-
tions) were better able to demonstrate proper use of their
medications compared to their counterparts receiving the stan-
dard label (OR 5.54, 95 % CI 1.09–28.07, p = 0.04). This was
also true among English speakers at 9 months, with those on
complex regimens in the PCL arm better demonstrating proper
use compared to the standard arm (OR 14.3, 95 % CI 1.23–
165.42, p = 0.03).
Regimen Adherence.Overall adherence rates by self-report at
3 and 9 months were 82.1 and 82.5 %, respectively, whereas
rates via pill count were 33.2 % and 30.8 %. There were no
differences between study arms at 3 months (self-report:
80.9 % [PCL] vs. 83.3 % [standard], p = 0.49; pill count:
35.8 % vs. 30.9 %, p = 0.32) or at 9 months (self-report:
85.8 % vs. 79.3 %, p = 0.07; pill count: 33.8 % vs. 28.0 %,
p = 0.26). However, in medication-level analyses, Spanish-
speaking patients receiving the PCL were more likely to self-
report higher rates at 9 months (OR 2.17, 95 % CI 0.99–4.73,
p = 0.05; Table 2). Significant interactions were found be-
tween study arm and daily dosing schedule and between study
arm and literacy level. At 3 months, English-speaking indi-
viduals in the PCL arm were significantly more likely than
those in the standard arm to be adherent (via pill count) to
prescribed regimens for medications taken two or more times
daily. Similar results were observed for the two arms with
once-a-day medications (OR 2.77, 95 % CI 1.17–6.53, p =
0.02).
The PCL intervention demonstrated a significant benefit for
patients with lower literacy skills in terms of both self-reported
and objectivelymeasured adherence via pill count at 9 months.
While there were no differences in adherence by study arm
Table 1 Participant Characteristics Stratified by Language
Characteristic English (n = 425) Spanish (n = 420)
Standard (N = 241) PCL (N = 184) Standard (N = 203) PCL (N = 217)
Age, mean years (SD) 52.4 (9.2) 51.8 (8.2) 53.7 (8.1) 51.6 (10.0) 52.6 (10.2)
Gender, %
Male 37.7 41.9 46.2 35.5 28.1
Female 62.3 58.1 53.8 64.5 71.9
Race/ethnicity, %
Black 23.2 42.7 50.0 0.5 0.0
White 14.7 27.0 29.9 0.5 1.4
Hispanic 50.3 3.7 2.7 98.0 97.7
Other 11.8 26.6 17.4 1.0 0.9
Education, %
<High school 42.9 25.8 23.0 63.9 59.3
High school grad/GED 25.2 34.6 34.4 13.9 17.6
Some college 18.7 24.2 24.6 10.9 14.8
College + 13.2 15.4 18.0 11.3 8.3
Literacy, %
Limited 37.4 37.9 39.6 38.4 34.1
Adequate 62.6 62.1 60.4 61.6 65.9
Table 2 Odds Ratios Comparing the PCL Strategy vs. Standard Care on the Outcomes of Proper Medication Use and Adherence*
Outcome Baseline 3 months 9 months
OR 95 % CI P value OR 95 % CI P value OR 95 % CI P value
All patients
Demonstrated proper use 1.16 0.88–1.52 0.30 1.19 0.78–1.81 0.43 1.67 1.06–2.63 0.03
Medication adherence
Self-report (PMAQ) — — — 0.93 0.57–1.52 0.76 1.59 0.93–2.74 0.09
Pill count — — — 1.24 0.85–1.80 0.27 1.13 0.75–1.71 0.55
English
Demonstrated proper use 1.21 0.78–1.88 0.40 1.37 0.70–2.68 0.36 2.21 1.13–4.31 0.02
Medication adherence
Self-report (PMAQ) — — — 1.06 0.51–2.19 0.88 1.06 0.50–2.27 0.88
Pill count — — 1.16 0.66–2.05 0.61 1.45 0.74–2.81 0.28
Spanish
Demonstrated proper use 1.21 0.85–1.72 0.28 1.10 0.64–1.90 0.73 1.19 0.63–2.24 0.59
Medication adherence
Self-report (PMAQ) — — — 0.87 0.41–1.82 0.71 2.17 0.99–4.73 0.05
Pill count — — — 1.27 0.77–2.10 0.35 0.93 0.54–1.58 0.78
*Standard care arm set as referent group
OR odds ratio, CI confidence interval, PMAQ Patient Medication Adherence Questionnaire
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among those with adequate literacy, patients with limited
literacy who received the PCL were more likely to demon-
strate proper adherence, both by self-report (OR 4.29, 95 % CI
0.94–19.49, p = 0.06) and by pill count (OR 5.08, 95 % CI
1.15–22.37, p = 0.03), than adults with limited literacy who
received standard labeling.
DISCUSSION
Our redesigned drug container label that included explicit
guidance on how to self-administer prescription regimens
demonstrated significant yet variable effects on proper medi-
cation use and adherence over 9 months. Specific benefits
were largely limited to English-speaking patients and certain
subgroups that have previously been found to be at greater risk
for unsafe medication use and non-adherence: adults with low
literacy and those taking more complex multi-drug regimens.
Interestingly, these patients had rates of adherence that were
comparable to, if not higher than, those who had adequate
literacy skills, were taking once-a-day regimens, or were con-
tending with fewer medications in their regimens. An earlier
evaluation of changes to a prescription drug container and
labeling did not find benefits to adherence or health out-
comes.32,33 While we cannot isolate the independent benefits
of the various label changes made with the PCL, the UMS is
one new, evidence-based labeling component not included in
the prior mentioned research investigations. To the best of our
knowledge, this is only the second investigation to evaluate
explicit changes to a prescription drug container label in actual
use, and the first to include the UMS. However, a number of
earlier studies support the acceptability and preference of the
many patient-centered modifications under study.34–36
The majority of patients did not receive a benefit from the
PCL, but in no instance didwe find that it performedworse than
standard labeling. As the intervention involved subtle modifi-
cations to pharmacy-generated labeling that could be readily
put into practice, set to scale, even small increases in proper use
and adherence among subgroups of consumers might yield a
cost benefit. From a local perspective, the implementation of
the PCL within the central-fill pharmacy used in this trial
included only a one-time cost of a programmer to make the
requisite changes to the labeling software allowing for the new
format, and the purchase of label paper that had a pre-printed
color highlight for the UMS instructions (as most pharmacies
do not have color printers). Importantly, the PCL did not require
any changes to typical pharmacy workflow.
Unfortunately, Spanish-speaking patients did not receive the
same benefit as their English-speaking counterparts. It is possible
that the translatedUMS terms for times of day did not adequately
account for the specific cultural backgrounds of the patients
involved in our study, despite previous findings showing success
in efficacy trials.24,37 Medication-related beliefs pertaining to
how prescribed drugs are to be taken also could have influenced
their behavior, and it is possible that the label instructions and
information were less impactful.38,39 Further study is needed to
better understand the unique needs of LEP patients.
Limitations
We partnered with a central-fill pharmacy that had a mandate
to provide services to patients whowere of low socioeconomic
status and representative of the most vulnerable patient pop-
ulations, by education, literacy, race/ethnicity, comorbidity,
and income. These community health settings made it difficult
not only to retain patients at follow-up, but also to readily
access data for purposes of both follow-up and exploratory
analyses examining the effects on intermediary clinical out-
comes. In addition, rates of adherence were very low in the
standard care arm, and despite marked gains among at-risk
groups, rates were also low in the intervention arm. However,
our findings are validated by other adherence studies that have
documented similar rates and have highlighted known socio-
economic disparities in adherence.40,41 Further research
should seek to generalize the effectiveness of the PCL among
a more diverse study sample from an array of ambulatory care
and pharmacy practices, not limited solely to settings serving
those that are socioeconomically disadvantaged.
There are several other limitations to our evaluation. In
order to maintain recruitment, we could not target only those
patients with newly prescribed treatments. The majority
(>90 %) were refills at baseline, and therefore patients already
had experience following these regimens.Wewere also unable
to collect data that would have allowed us to calculate ratios of
medication possession or proportion of days covered, due to
the manner in which refills were generated by the central-fill
pharmacy. Specifically, a change to protocols at the participat-
ing clinics did not allow for a valid recorded patient Bpick-up^
date, just the courier delivery date. However, we were able to
monitor adherence via pill count, which is a better reflection of
medication use over time than simply refill dates.42 Although
our pill count outcome did not correlate well with our self-
report measure, this is a known phenomenon and is not sur-
prising. A recent study by Agot et al. and a review of the
literature across many disease contexts both found similar
trends of patients self-reporting much higher adherence than
observed with pill count.43,44 Yet another limitation, which
also should not be surprising, is that the majority of medica-
tions taken by study participants were once-a-day (74.7 %)
and twice-a-day prescriptions (24.0 %). Only 1.2 % were for
more complex schedules. The value of the UMS would likely
be greater for medications with more dosing ambiguity, re-
quiring spacing of daily doses (i.e. morning and evening vs.
twice daily). Our findings therefore may offer only conserva-
tive estimates of the effectiveness of the PCL strategy and
UMS among patients with more complicated regimens who
need help in finding the most efficient daily schedule and in
sustaining adherence over time.
As there were many components to the PCL, it was not
possible to separate the independent contributions of each,
1487Wolf et al.: A Patient-Centered Prescription Drug LabelJGIM
especially the graphic aid from the UMS instruction itself. The
latter would be easier for most pharmacies to accept and
implement. Furthermore, many patients used more than one
pharmacy for their medications, so the PCL strategy and UMS
were likely included in only a portion of their complete Rx
regimen, diluting the effect. Finally, our use of two different
literacy measures, the REALM and SAHLSA, may have set a
different threshold of literacy for English and Spanish-
speaking patients, given the discordance in assessment. Al-
though the development of the SAHLSA is derived from the
REALM, and the two measures are strongly correlated, this
could have impacted findings, but was a decision made at trial
initiation based on options available at the time.
Conclusions
Our study is the first to test our patient-centered label strategy
with the UMS in actual use. Overall, these patient-centered
changes to a drug label offered some modest and targeted
benefits, particularly for individuals with more limited literacy
and those with polypharmacy challenges. The variable findings
by language make it difficult to fully understand the potential
benefits and/or challenges experienced by either patient group.
In light of the lack of evidence of any detrimental effects of the
PCL strategy with regard to patients’ medication use, coupled
with the results of previous efficacy studies, we believe that the
PCL and UMS may still represent a potential practice standard
with further study. Kenning and colleagues recently found the
UMS to be an acceptable practice from the perspective of not
only patients, but physicians and pharmacists as well.45 From a
broader view, it is unrealistic to expect that merely making a
basic change to the language and organization of a drug con-
tainer label would be able to sustain such a formidable behavior
change or improve intermediary outcomes. However, it is
reasonable to think that clear, explicit labeling could contribute
to a better understanding of how to organize and simplify a
daily drug regimen.
The evidence is strong that current drug labeling practices
pose risks to both patient safety and adherence, and research is
needed to guide policies that can establish a unified set of
standards across all states. California has already enacted
legislation implementing many of these practices.46 Clearly,
further evaluation is needed to examine how pharmacy label-
ing changes can benefit patients, especially those with the
most complex conditions and multi-drug regimens.
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